Repligen Corporation Company Profile (NASDAQ:RGEN)

About Repligen Corporation

Repligen Corporation logoRepligen Corporation is a bioprocessing company. The Company is focused on the development, production and commercialization of products used in the process of manufacturing biologic drugs (bioprocessing). The Company is a manufacturer of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug. The Company also supplies several growth factor products, Alternating Tangential Flow (ATF) System products and cell filtration products used to increase cell culture productivity during the bioproduction process. The Company has developed a series of OPUS chromatography columns for use in clinical-scale manufacturing. The Company manufactures and sells Protein A and growth factors to life sciences companies under long-term supply agreements and sells its chromatography columns, as well as media and quality test kits.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: RGEN
  • CUSIP: 75991610
Key Metrics:
  • Previous Close: $30.89
  • 50 Day Moving Average: $30.43
  • 200 Day Moving Average: $30.97
  • 52-Week Range: $33,831,000.00 - $21.11
  • Trailing P/E Ratio: 149.86
  • Foreward P/E Ratio: 56.40
  • P/E Growth: 2.81
  • Market Cap: $1.05B
  • Outstanding Shares: 33,831,000
  • Beta: 1.58
Profitability:
  • Net Margins: 6.89%
  • Return on Equity: 10.16%
  • Return on Assets: 6.87%
Debt:
  • Debt-to-Equity Ratio: 0.57%
  • Current Ratio: 10.89%
  • Quick Ratio: 9.68%
Additional Links:
Companies Related to Repligen Corporation:

Analyst Ratings

Consensus Ratings for Repligen Corporation (NASDAQ:RGEN) (?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $23.52 (24.17% downside)

Analysts' Ratings History for Repligen Corporation (NASDAQ:RGEN)
Show:
DateFirmActionRatingPrice TargetDetails
2/13/2017Piper Jaffray CompaniesUpgradeNeutral -> Overweight$3.57View Rating Details
12/21/2016Jefferies Group LLCReiterated RatingHold$28.00 -> $30.00View Rating Details
12/18/2016StephensSet Price TargetBuy$37.00View Rating Details
2/22/2016Craig HallumInitiated CoverageBuyView Rating Details
(Data available from 2/19/2015 forward)

Earnings

Earnings History for Repligen Corporation (NASDAQ:RGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/23/2017        
11/3/2016Q316$0.08$0.08$24.39 million$24.70 millionViewN/AView Earnings Details
8/4/2016Q216$0.13$0.16$24.75 million$29.20 millionViewN/AView Earnings Details
5/5/2016Q116$0.10$0.12$22.54 million$25.10 millionViewN/AView Earnings Details
2/25/2016Q415$0.07$0.07$19.84 million$21.40 millionViewListenView Earnings Details
11/5/2015Q315$0.08$0.08$20.50 million$19.80 millionViewN/AView Earnings Details
8/6/2015Q215$0.08$0.11$20.05 million$21.50 millionViewN/AView Earnings Details
5/7/2015Q115$0.07$0.09$18.20 million$20.82 millionViewN/AView Earnings Details
3/13/2015Q414$0.04($0.01)$14.70 million$15.40 millionViewN/AView Earnings Details
11/6/2014Q314$0.04$0.04$15.60 million$15.30 millionViewN/AView Earnings Details
8/11/2014Q114$0.06$0.09$14.90 million$15.60 millionViewN/AView Earnings Details
5/8/2014Q1$0.07$0.13$15.14 million$16.33 millionViewListenView Earnings Details
3/6/2014Q413$0.14$0.10$15.88 million$10.40 millionViewListenView Earnings Details
11/7/2013Q313$0.13$0.18$16.27 million$18.80 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.10$0.14$15.97 million$17.50 millionViewListenView Earnings Details
5/2/2013Q1 2013$0.07$12.82 million$16.46 millionViewListenView Earnings Details
11/8/2012Q312$0.06$8.63 million$15.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Repligen Corporation (NASDAQ:RGEN)
Current Year EPS Consensus Estimate: $0.44 EPS
Next Year EPS Consensus Estimate: $0.55 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.10$0.10$0.10
Q2 20161$0.12$0.12$0.12
Q3 20161$0.11$0.11$0.11
Q4 20162$0.06$0.12$0.09
Q1 20172$0.12$0.13$0.13
Q2 20172$0.15$0.17$0.16
Q3 20172$0.11$0.11$0.11
Q4 20172$0.10$0.12$0.11
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Repligen Corporation (NASDAQ:RGEN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Repligen Corporation (NASDAQ:RGEN)
Insider Ownership Percentage: 2.30%
Institutional Ownership Percentage: 94.35%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/28/2016Anthony HuntCEOSell5,000$33.12$165,600.00View SEC Filing  
9/14/2016Thomas F Ryan JrDirectorSell2,700$32.58$87,966.00View SEC Filing  
6/30/2016Thomas F Ryan JrDirectorSell5,000$26.60$133,000.00View SEC Filing  
6/28/2016Thomas F Ryan JrDirectorSell10,000$24.59$245,900.00View SEC Filing  
5/11/2016Howard BenjaminVPSell2,889$26.72$77,194.08View SEC Filing  
6/9/2015Howard BenjaminVPSell35,000$38.14$1,334,900.00View SEC Filing  
5/11/2015Walter C HerlihyCEOSell104,569$37.94$3,967,347.86View SEC Filing  
5/8/2015Thomas F Ryan JrDirectorSell20,000$37.19$743,800.00View SEC Filing  
3/23/2015Walter C HerlihyCEOSell24,536$31.78$779,754.08View SEC Filing  
3/19/2015James R RuscheSVPSell14,650$33.30$487,845.00View SEC Filing  
3/19/2015Thomas F Ryan JrDirectorSell10,000$32.62$326,200.00View SEC Filing  
3/19/2015Walter C HerlihyCEOSell49,695$33.08$1,643,910.60View SEC Filing  
3/18/2015Howard BenjaminVPSell15,795$32.63$515,390.85View SEC Filing  
11/19/2014Walter C HerlihyCEOSell51,386$23.43$1,203,973.98View SEC Filing  
11/13/2014Thomas F Ryan JrDirectorSell10,000$23.81$238,100.00View SEC Filing  
11/11/2014Howard BenjaminVPSell30,000$23.56$706,800.00View SEC Filing  
11/10/2014Michael A GriffithDirectorSell23,342$22.90$534,531.80View SEC Filing  
8/13/2014Howard BenjaminVPSell40,000$20.34$813,600.00View SEC Filing  
6/27/2014Thomas F Ryan JrDirectorSell10,000$22.41$224,100.00View SEC Filing  
6/24/2014Thomas F Ryan JrDirectorSell10,000$21.78$217,800.00View SEC Filing  
6/11/2014Walter C HerlihyCEOSell60,335$20.11$1,213,336.85View SEC Filing  
6/9/2014James R RuscheSVPSell30,000$20.19$605,700.00View SEC Filing  
6/6/2014Daniel P WittSVPSell47,709$20.56$980,897.04View SEC Filing  
4/15/2014Daniel P WittSVPBuy10,000$3.05$30,500.00View SEC Filing  
8/8/2013James R RuscheSVPSell30,000$10.01$300,300.00View SEC Filing  
6/21/2013Karen A DawesDirectorBuy1,000$7.70$7,700.00View SEC Filing  
5/17/2013Thomas F Ryan JrDirectorSell21,000$8.97$188,370.00View SEC Filing  
5/15/2013Thomas F Ryan JrDirectorSell86,039$9.01$775,211.39View SEC Filing  
5/15/2013Walter C HerlihyCEOSell40,000$8.97$358,800.00View SEC Filing  
9/21/2012Glenn L Md CooperDirectorBuy10,000$6.09$60,900.00View SEC Filing  
8/16/2012Michael A GriffithDirectorBuy2,000$4.88$9,760.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Repligen Corporation (NASDAQ:RGEN)
DateHeadline
News IconIs The Sell-Side Predicting That Repligen Corporation (NASDAQ:RGEN) Will Move Higher? - Winfield Review (NASDAQ:RGEN)
winfieldreview.com - February 17 at 7:57 PM
finance.yahoo.com logoRepligen To Report Fourth Quarter and Full Year 2016 Financial Results, Provides Financial Guidance for 2017 (NASDAQ:RGEN)
finance.yahoo.com - February 16 at 7:09 PM
News IconRepligen Corporation (RGEN) is Upgraded by Piper Jaffray to ” Overweight” - Highland Mirror (NASDAQ:RGEN)
www.highlandmirror.com - February 14 at 5:37 AM
finance.yahoo.com logoRepligen upgraded by Piper Jaffray (NASDAQ:RGEN)
finance.yahoo.com - February 14 at 5:37 AM
finance.yahoo.com logoThe Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Dr. Reddy's Laboratories, BioMarin Pharmaceutical and Repligen (NASDAQ:RGEN)
finance.yahoo.com - February 7 at 12:39 AM
News IconStock Tracker: Earnings & Estimates for Repligen Corporation (NASDAQ:RGEN) - Aiken Advocate (NASDAQ:RGEN)
aikenadvocate.com - January 31 at 9:54 PM
realistinvestor.com logoRepligen Corporation (NASDAQ:RGEN) Analysts Rating At 1.67 (NASDAQ:RGEN)
www.realistinvestor.com - January 30 at 8:12 PM
News IconGearing Up For a Bull Run? Analysts Weigh in on Repligen Corporation (NASDAQ:RGEN) - Wall Street Beacon (NASDAQ:RGEN)
wsbeacon.com - January 20 at 6:30 AM
News IconWill The Needle Move For Repligen Corporation (NASDAQ:RGEN) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:RGEN)
wsbeacon.com - January 18 at 12:56 AM
News IconDid Repligen Corporation (RGEN) Create Value For Shareholders Over The Past One Year? (NASDAQ:RGEN)
simplywall.st - January 17 at 7:55 PM
seekingalpha.com logoRepligen Corporation (RGEN) Presents At 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:RGEN)
seekingalpha.com - January 14 at 5:41 AM
News IconStock in Focus: Repligen Corporation (NASDAQ:RGEN) - Wall Street Beacon (NASDAQ:RGEN)
wsbeacon.com - January 9 at 8:36 AM
News IconRepligen Corp RGEN Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:RGEN)
www.bioportfolio.com - January 8 at 12:10 AM
globenewswire.com logoRepligen to Present at 35th Annual J.P. Morgan Healthcare Conference - GlobeNewswire (press release) (NASDAQ:RGEN)
globenewswire.com - January 5 at 1:17 AM
us.rd.yahoo.com logoRepligen to Present at 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:RGEN)
us.rd.yahoo.com - January 4 at 8:16 PM
capitalcube.com logoRepligen Corp. – Value Analysis (NASDAQ:RGEN) : January 3, 2017 (NASDAQ:RGEN)
www.capitalcube.com - January 4 at 12:22 AM
News IconRepligen Corporation (RGEN): Is it a good long term opportunity? (NASDAQ:RGEN)
simplywall.st - January 3 at 9:58 AM
realistinvestor.com logoThe Growth Predict For Repligen Corporation (NASDAQ:RGEN) (NASDAQ:RGEN)
www.realistinvestor.com - January 2 at 7:18 PM
capitalcube.com logoRepligen Corp. breached its 50 day moving average in a Bearish Manner : RGEN-US : January 2, 2017 (NASDAQ:RGEN)
www.capitalcube.com - January 2 at 7:18 PM
realistinvestor.com logoRepligen Corporation (NASDAQ:RGEN) Bearish Stock Price Estimate At 1.67 - RealistInvestor.com (NASDAQ:RGEN)
www.realistinvestor.com - December 26 at 6:48 PM
News IconChecking the Levels on Shares of Repligen Corporation (NASDAQ:RGEN) - The Business Journal (NASDAQ:RGEN)
belmontbusinessjournal.com - December 21 at 8:38 AM
News IconChecking the Levels on Shares of Repligen Corporation (NASDAQ ... - The Business Journal (NASDAQ:RGEN)
belmontbusinessjournal.com - December 20 at 7:16 PM
News IconFocusing on the Charts for Repligen Corporation (RGEN) - Yankee Analysts (NASDAQ:RGEN)
yankeeanalysts.com - December 19 at 12:52 AM
4-traders.com logoRepligen Corporation : Blog Coverage Repligen Acquires Maker of Tangential Flow Filtration Cassettes (NASDAQ:RGEN)
www.4-traders.com - December 17 at 2:22 AM
finance.yahoo.com logo6:58 am Repligen acquires TangenX Technology for $39 mln in cash; RGEN expects earnings accretion in 2017 (NASDAQ:RGEN)
finance.yahoo.com - December 16 at 12:34 AM
finance.yahoo.com logoRepligen Acquires TangenX Technology Corporation (NASDAQ:RGEN)
finance.yahoo.com - December 16 at 12:34 AM
finance.yahoo.com logoUPDATE -- Repligen Acquires TangenX Technology Corporation (NASDAQ:RGEN)
finance.yahoo.com - December 16 at 12:34 AM
finance.yahoo.com logoNovasep Sells U.S. Subsidiary TangenX Technology Corporation, Innovator in Tangential Flow Filtration for Biopharmaceuticals (NASDAQ:RGEN)
finance.yahoo.com - December 16 at 12:34 AM
biz.yahoo.com logoREPLIGEN CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or Dispositio (NASDAQ:RGEN)
biz.yahoo.com - December 16 at 12:34 AM
seekingalpha.com logoRepligen buys TangenX Technology; expected to be accretive to EPS in 2017 (NASDAQ:RGEN)
seekingalpha.com - December 15 at 8:25 AM
News IconPrice Index Watch on Shares of Repligen Corporation (NASDAQ:RGEN) - The Business Journal (NASDAQ:RGEN)
belmontbusinessjournal.com - December 14 at 8:05 AM
News IconInvestors are Looking at Levels for Repligen Corporation (RGEN) - StockTalk Daily (NASDAQ:RGEN)
stocktalkdaily.com - December 14 at 8:05 AM
News IconCompany Stock in Focus: Repligen Corporation (NASDAQ:RGEN) - Business Daily Leader (NASDAQ:RGEN)
businessdailyleader.com - December 13 at 8:20 AM
insidermonkey.com logoIs Repligen Corporation (RGEN) a Good Stock to Buy? - Insider Monkey (blog) (NASDAQ:RGEN)
www.insidermonkey.com - December 11 at 9:15 AM
News IconIs Repligen Corporation (RGEN) a Good Stock to Buy? (NASDAQ:RGEN)
feedproxy.google.com - December 10 at 7:31 PM
News IconTrading Insight: Taking a Look at Levels for Repligen Corporation (RGEN) - StockTalk Daily (NASDAQ:RGEN)
stocktalkdaily.com - December 1 at 12:42 AM
News IconStock Concentration on Shares of Repligen Corporation (NASDAQ:RGEN) - Wall Street Beacon (NASDAQ:RGEN)
wsbeacon.com - December 1 at 12:42 AM
News IconSEC Insider Narrative: Is Repligen Corporation (NASDAQ:RGEN) Stock a Sell after Anthony Hunt’s Insider Trading? (NASDAQ:RGEN)
www.whatsonthorold.com - November 30 at 12:34 PM
News IconInside the Numbers for Repligen Corporation (NASDAQ:RGEN) - Wall Street Beacon (NASDAQ:RGEN)
wsbeacon.com - November 29 at 1:48 PM
News IconVolatility Levels in Focus for Repligen Corporation (NASDAQ:RGEN) - Wall Street Lion (NASDAQ:RGEN)
wslnews.com - November 25 at 12:20 PM
News IconVC Score In Focus for Repligen Corporation (NASDAQ:RGEN) - Marion Business Daily (NASDAQ:RGEN)
marionbusinessdaily.com - November 23 at 7:25 PM
News IconInvestor Update: Tracking Shares of Repligen Corporation (NASDAQ:RGEN) - Marion Business Daily (NASDAQ:RGEN)
marionbusinessdaily.com - November 20 at 6:52 PM
News IconNarrowing in on Trading Indicators for Repligen Corporation (RGEN) - StockTalk Daily (NASDAQ:RGEN)
stocktalkdaily.com - November 20 at 6:52 PM
finance.yahoo.com logoREPLIGEN CORP Financials (NASDAQ:RGEN)
finance.yahoo.com - November 11 at 10:01 AM
capitalcube.com logoRepligen Corp. breached its 50 day moving average in a Bullish Manner : RGEN-US : November 11, 2016 (NASDAQ:RGEN)
www.capitalcube.com - November 11 at 10:01 AM
News IconTime to pull the Trigger or Plug on Repligen Corporation (NASDAQ:RGEN) - CSZ News (NASDAQ:RGEN)
cincysportszone.com - November 10 at 7:03 PM
realistinvestor.com logoThe Growth Forecast For:Repligen Corporation (NASDAQ:RGEN) - RealistInvestor.com (NASDAQ:RGEN)
www.realistinvestor.com - November 8 at 10:43 AM
realistinvestor.com logoThe Growth Forecast For:Repligen Corporation (NASDAQ:RGEN) (NASDAQ:RGEN)
www.realistinvestor.com - November 7 at 7:57 PM
finance.yahoo.com logoRepligen to Participate in Stephens Inc. Fall Investment Conference 2016 (NASDAQ:RGEN)
finance.yahoo.com - November 7 at 7:57 PM
seekingalpha.com logoRepligen's (RGEN) CEO Tony Hunt on Q3 2016 Results - Earnings Call Transcript (NASDAQ:RGEN)
seekingalpha.com - November 4 at 6:42 PM

Social

What is Repligen Corporation's stock symbol?

Repligen Corporation trades on the NASDAQ under the ticker symbol "RGEN."

Where is Repligen Corporation's stock going? Where will Repligen Corporation's stock price be in 2017?

4 equities research analysts have issued 12-month price targets for Repligen Corporation's stock. Their forecasts range from $3.57 to $37.00. On average, they anticipate Repligen Corporation's stock price to reach $23.52 in the next year.

When will Repligen Corporation announce their earnings?

Repligen Corporation is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.

Who owns Repligen Corporation stock?

Repligen Corporation's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (3.84%), State Street Corp (3.13%), Dimensional Fund Advisors LP (2.88%), Ranger Investment Management L.P. (2.81%), Renaissance Technologies LLC (2.64%) and Federated Investors Inc. PA (2.50%). Company insiders that own Repligen Corporation stock include Anthony Hunt, Howard Benjamin, James R Rusche, Thomas F Ryan Jr and Walter C Herlihy.

Who sold Repligen Corporation stock? Who is selling Repligen Corporation stock?

Repligen Corporation's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Columbia Wanger Asset Management LLC, Renaissance Technologies LLC, Royce & Associates LP, Allianz Asset Management AG, Dimensional Fund Advisors LP, Two Sigma Investments LP and AQR Capital Management LLC. Company insiders that have sold Repligen Corporation stock in the last year include Anthony Hunt, Howard Benjamin and Thomas F Ryan Jr.

Who bought Repligen Corporation stock? Who is buying Repligen Corporation stock?

Repligen Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Ranger Investment Management L.P., Russell Investments Group Ltd., State Street Corp, Arrowpoint Asset Management LLC, Capstone Investment Advisors LLC, William Blair Investment Management LLC, Comerica Bank and Thrivent Financial for Lutherans.

How do I buy Repligen Corporation stock?

Shares of Repligen Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Repligen Corporation stock cost?

One share of Repligen Corporation stock can currently be purchased for approximately $31.02.

Repligen Corporation (NASDAQ:RGEN) Chart for Sunday, February, 19, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Repligen Corporation (NASDAQ:RGEN)

Earnings History Chart

Earnings by Quarter for Repligen Corporation (NASDAQ:RGEN)

Dividend History Chart

Dividend Payments by Quarter for Repligen Corporation (NASDAQ:RGEN)

Last Updated on 2/19/2017 by MarketBeat.com Staff